## EW: Edwards Lifesciences Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 1.2% below STRENGTH zone (4.0-10.0%); PEG 4.78 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($82.88)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. How JP Morgan’s Upgrade and 2026 Conference Spotlight Will Impact Edwards Lifesciences (EW) Investors**
- Source: Simply Wall Street | 20251222T033246 | Somewhat-Bullish | Relevance: 100%
- Edwards Lifesciences (EW) will participate in the 44th Annual J.P. Morgan Healthcare Conference in January 2026, coinciding with a recent JP Morgan analyst upgrade to Overweight with a $100 price target. This increased analyst confidence highlights the market's close attention to Edwards' cardiovascular innovation roadmap. While the conference and upgrade bring positive attention to products like early TAVR and EVOQUE, key challenges remain around regulatory progress, tariffs, acquisition dilution, and international competition.

**2. Edwards Lifesciences Corporation $EW Shares Sold by Texas Permanent School Fund Corp**
- Source: MarketBeat | 20251220T103101 | Neutral | Relevance: 100%
- The Texas Permanent School Fund Corp significantly reduced its stake in Edwards Lifesciences (NYSE:EW) by 35.4% in Q2, selling 22,542 shares and leaving its holding valued at $3.22 million. Company insiders have also been net sellers, liquidating 45,465 shares worth approximately $3.8 million over the past 90 days. Despite this insider selling, analysts maintain a "Moderate Buy" rating with a consensus price target of $93.95, following the company's strong Q3 earnings beat and positive FY2025 guidance.

**3. Seilern Investment Management Ltd Sells 183,101 Shares of Edwards Lifesciences Corporation $EW**
- Source: MarketBeat | 20251222T110830 | Somewhat-Bullish | Relevance: 98%
- Seilern Investment Management Ltd reduced its stake in Edwards Lifesciences Corporation by 14.8%, selling 183,101 shares and now holding 1,055,774 shares valued at approximately $82.1 million. The article notes that insider selling has occurred this quarter, while institutional investors own a significant portion of the stock. Analyst sentiment remains bullish-to-neutral with a "Moderate Buy" consensus rating and a $93.95 target price, following Edwards Lifesciences' recent positive quarterly results and FY2025 EPS guidance.

**4. Tim Schmid shares Johnson & Johnson MedTech’s growth playbook**
- Source: Medical Design & Outsourcing | 20251222T140323 | Neutral | Relevance: 66%
- Tim Schmid, EVP and global medtech chairman of Johnson & Johnson MedTech, outlines the company's new growth strategy, which includes spinning off DePuy Synthes to focus on cardiovascular, surgery, and vision. This strategic shift, bolstered by acquisitions like Abiomed and Shockwave Medical, aims to increase J&J MedTech's presence in high-growth markets and improve its financial performance. Schmid also discusses the future of J&J's surgical robotics (Ottava), vision business, and ongoing M&A and R&D investments.

**5. Abbott earns FDA approval for Volt PFA system for AFib**
- Source: MassDevice | 20251222T140352 | Somewhat-Bullish | Relevance: 57%
- Abbott has received FDA approval for its Volt pulsed field ablation (PFA) system for treating atrial fibrillation (AFib), making it a new competitor in the U.S. PFA market. The system offers a single-catheter PFA approach, designed for improved workflow and procedural flexibility, and allows for conscious sedation, potentially leading to faster recovery times. This approval, based on strong data from the VOLT-AF IDE study, was granted ahead of analyst expectations and is anticipated to intensify competition in the PFA market.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 11, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | JP Morgan | $100 | $90 | +11% |
| 2025-12-17 | Canaccord Genui | $87 | $89 | -2% |
| 2025-12-16 | Baird | $87 | $88 | -1% |
| 2025-12-11 | Citigroup | $101 | $96 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | JP Morgan | up | Overweight |
| 2025-12-17 | Canaccord Genui | main | Hold |
| 2025-12-16 | Baird | main | Neutral |
| 2025-12-11 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 12 ($3.78M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+0.5%)
- Blackrock Inc.: 9.4% (-2.4%)
- JPMORGAN CHASE & CO: 8.6% (+87.2%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.6% (+4.9%)

### Key Risks

1. Insider selling cluster: $3.8M in recent transactions.
2. Valuation stretched: PEG 4.8x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 11 raises (avg +5%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.78 signals overvaluation risk, limited margin of safety. Forward P/E 30.1x stretched relative to 11% growth. Quality metrics strong (margin 23%). Balance sheet: strong liquidity (4.0x), low leverage (D/E 0.30). Insider selling cluster ($3.8M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $50.8B |
| Beta | 0.97 |
| 52W Range | $65.94 - $87.89 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.78 |
| Forward P/E | 30.1 |
| Current P/E | 33.5 |
| YoY Growth | 11.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+0.6% over 5 days). Below STRENGTH zone by 2.8pp (needs >4.0% for momentum thesis). MRS_5 (-0.1%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 59. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.16% (CS: 59) | Neutral |
| RSI_14 | 59.4 | Neutral |
| MACD Histogram | -0.02 | Bearish |
| vs SMA20 | 1.018x | Above |
| vs SMA50 | 1.048x | Above |
| vs SMA200 | 1.117x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $86.50
- **Stop Loss:** $82.88 (4.2% risk)
- **Target:** $90.12 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 331
- **Position Value:** $28,631.50
- **Portfolio %:** 28.63%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-11 (Est: $0.62)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.59 | $0.67 | +12.6% |
| 2025Q2 | $0.62 | $0.67 | +7.6% |
| 2025Q1 | $0.60 | $0.64 | +7.5% |
| 2024Q4 | $0.55 | $0.59 | +6.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*